Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hightide Therapeutics Inc ( (HK:2511) ) has shared an announcement.
HighTide Therapeutics announced that their lead compound, HTD1801, met the primary endpoints in two Phase 3 clinical trials for patients with type 2 diabetes mellitus. The trials, named SYMPHONY 1 and SYMPHONY 2, demonstrated significant glucose-lowering effects and improvements in cardiometabolic risk indicators. Based on these results, HighTide plans to submit a new drug application for HTD1801 in China. The trials also showed favorable safety and tolerability profiles, with minimal adverse events reported.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a company incorporated in the Cayman Islands, focusing on the development of innovative therapies for metabolic and digestive diseases. Their primary product is HTD1801, a gut-liver anti-inflammatory metabolic modulator, which is being developed for multiple indications including type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH).
YTD Price Performance: 11.81%
Average Trading Volume: 1,015,966
Technical Sentiment Signal: Hold
Current Market Cap: HK$731M
See more insights into 2511 stock on TipRanks’ Stock Analysis page.